Compare VRA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ICCC |
|---|---|---|
| Founded | 1982 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 93.1M |
| IPO Year | 2010 | 1995 |
| Metric | VRA | ICCC |
|---|---|---|
| Price | $3.29 | $10.02 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.4K | 26.0K |
| Earning Date | 06-10-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.47 | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $416,097,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ N/A | $24.39 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.39 | $4.52 |
| 52 Week High | $4.39 | $12.10 |
| Indicator | VRA | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 43.61 |
| Support Level | $3.03 | $9.36 |
| Resistance Level | $3.51 | $10.75 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 58.97 | 47.70 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.